A Case of Immune Thrombocytopenia as a Rare Side Effect of an Immunotherapy with PD1-Blocking Agents for Metastatic Melanoma

Abstract

Background: Checkpoint blocking agents such as pembrolizumab or nivolumab may induce a diversity of mostly autoimmune-mediated side effects. These autoimmune phenomena mainly affect ductless glands such as the pituitary gland (hypophysitis), the thyroid gland (thyreoiditis), the skin (vitiligo and rash), the colon (colitis), and the lung (pneumonitis). Furthermore, many other organs or organ systems may be affected. Case Report: This work describes a case of an immune thrombocytopenia that developed or rather became clinically significant shortly after initiation of a systemic therapy with first nivolumab and later pembrolizumab given due to metastatic melanoma. Platelet counts before this systemic therapy were slightly decreased with values around 110/nl (normal value 140-400/nl). Thrombocytopenia developed or became apparent rapidly within 10 days after the first intravenous application of nivolumab and worsened after changeover to pembrolizumab. Therapy had to be stopped due to disease progression and steady aggravation of thrombocytopenia. Immune hematology assays could prove an autoimmune mediated genesis of thrombocytopenia. Conclusion: Checkpoint inhibitors may induce a multiplicity of mostly autoimmune-mediated side effects. In contrast to chemotherapy-induced cytopenia that results from bone marrow toxicity, thrombocytopenia in melanoma patients treated with checkpoint inhibiting substances seems to result from autoimmune-mediated side effects in the majority of the cases. Thorough laboratory controls during these therapies are therefore required. In case of thrombocytopenia, immune hematology testing to diagnose or rule out immune thrombocytopenia is indispensable.

An Episode of Pseudothrombocytopenia during Pembrolizumab Therapy in NSCLC Patient

“…Cases of immune thrombocytopenia have been observed and described previously in melanoma patients treated with nivolumab, ipilimumab, or pembrolizumab. However, there were no cases of EDTA-dependent PTCP [24,25].…”

Nivolumab-induced immune thrombocytopenia in a patient with malignant pleural mesothelioma

“…In our patient, the PA-IgG level increased when ITP occurred and then decreased after ITP treatment was initiated. In several case reports, elevated PA-IgG levels have been observed in patients with ICI-induced ITP [ 19 , 20 ]. Although further investigation regarding the frequency of occurrence and the clinical impact of antinuclear antibodies and PA-IgG levels in ICI-induced ITP is required, the presence of these antibodies might be related to the cause of ICI-induced ITP.…”

Biointerface engineering nanoplatforms for cancer-targeted drug delivery

“…However, with its widespread clinical application, some problems have emerged. They include immunotherapy-associated side effects and relatively lower treatment efficiency [3] , [4] , [5] . Besides, a perplexing issue is the susceptibility of some, but not all, patients to immunotherapy.…”